Sort
82,697 grants matching “vaccine development”
Genetic and Immuno-inflammatory Drivers of Post-acute Pulmonary Sequelae of SARS-CoV-2
$830,331Steven B Abramson · New York University School Of Medicine · R01 · FY2024 · HL
Transcutaneous Immunization for Tetanus Booster
$830,292Iomai Corporation · R44 · FY2003 · AI
Antidotes to Anthrax Lethal Factor Intoxication
$830,000Alan Thomas Johnson · Panthera Biopharma, Llc · U01 · FY2008 · AI
COVID-19 Vaccinations and School / Community Resources: Children's Longitudinal Health and Education Outcomes Using Linked Administrative Data
$829,896Brian Elbel · New York University School Of Medicine · U01 · FY2021 · NR
Global Analysis of Cellular Networks Involved In Restriction of HIV Replication
$829,875Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2014 · AI
Host-pathogen interactions during hospital adaptation of MRSA
$829,843Bo Shopsin · New York University School Of Medicine · R01 · FY2020 · AI
Project II: Immunity to Influenza in Primary Lung Dendritic Cells
$829,779Stuart C. Sealfon · Icahn School Of Medicine At Mount Sinai · U19 · FY2018 · AI
Early Innate/IgA Anti-HIV/SIV Response in Exposed Uninfected
$829,776Luis J. Montaner · Wistar Institute · R01 · FY2011 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy
$829,756Priscilla Li-Ning Yang · Harvard Medical School · R01 · FY2020 · AI
Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP
$829,746Oreola Donini · Soligenix, Inc. · R44 · FY2022 · AI
Development of an oral liver-targeted prime-and-trap malaria vaccine
$829,705Sean C Murphy · University Of Washington · U01 · FY2024 · AI
Identification of Novel Mucosal Immune Mechanisms Involved in Protection from HIV-1
$829,628Jennifer M Lund · Fred Hutchinson Cancer Research Center · R01 · FY2019 · AI
Novel Therapeutics for Biodefense
$829,558Paratek Pharmaceuticals · R43 · FY2004 · AI
Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS Factor
$829,516Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
HIV-1 Env protein structure and function assessed by parallel smFRET and cryoET
$829,461Walther H Mothes · Yale University · R37 · FY2023 · AI
A universal MHC-E-restricted T cell vaccine for HIV
$829,438Jonah B. Sacha · Oregon Health & Science University · R01 · FY2016 · AI
BSL4 Evaluation Core
$829,380Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2014 · AI
Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIV
$829,262Rachel Lena Rutishauser · University Of California, San Francisco · R01 · FY2024 · AI
Defining HIV reservoirs that rebound following suspension of ART
$829,247Lisa M Frenkel · Seattle Children'S Hospital · R01 · FY2017 · AI
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
$829,193Carlos Rafael Oliveira · Yale University · R01 · FY2024 · AI
Human Genes that Influence HIV-1 Replication, Pathogenesis, and Immunity in IVDUs
$829,125Jeremy Luban · Univ Of Massachusetts Med Sch Worcester · DP1 · FY2016 · DA
Characterizing pediatric genomes through an optimized sequencing approach
$829,064Shawn E Levy · Hudson-Alpha Institute For Biotechnology · U24 · FY2020 · HD
Attenuating Inflammation to Restore GI Tract Integrity and Reduce Viral Reservoirs During cART
$829,058Jacob D Estes · Oregon Health & Science University · R01 · FY2018 · DK
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: CLINICAL CORE
$828,793Kathleen Neuzil · University Of Maryland Baltimore · N01 · FY2022 · AI
Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients
$828,717Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2024 · AI